Jpmorgan Chase & CO Galectin Therapeutics Inc Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11,721 shares of GALT stock, worth $29,185. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,721
Previous 1,871
526.46%
Holding current value
$29,185
Previous $4,000
550.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding GALT
# of Institutions
77Shares Held
9.36MCall Options Held
982KPut Options Held
2.7K-
Vanguard Group Inc Valley Forge, PA2.12MShares$5.27 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$3.89 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.13MShares$2.8 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA842KShares$2.1 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.2 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $148M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...